Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Фаза 3
Идёт, набор закрыт
NCT02562235
| Заболевание | Hypertension, Pulmonary |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Bayer |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 24 участн. |
|---|
| Вмешательство | Riociguat (Adempas, BAY63-2521) |
|---|
| Дата начала | 29.10.2015 |
|---|
| Дата завершения | 7.03.2020 |
|---|
| Публикация результатов | 17.05.2021 |
|---|
Кратко
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.
Number of Participants With Any Treatment-emergent Adverse Events
From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days. · Participants
| Riociguat >=6 to <18 Years | 20 Participants |
|---|
| Riociguat >=6 to <18 Years | 4 Participants |
|---|
Change in Heart Rate From Baseline
Baseline and Week 24 (plus/minus 5 days) · Beats per minute (BPM)
| Riociguat >=6 to <18 Years | 4.1 ± 10.1 Beats per minute (BPM) |
|---|
Change in Blood Pressure From Baseline
Baseline and Week 24 (plus/minus 5 days) · millimetre of mercury (mmHg)
| Riociguat >=6 to <18 Years | -3.1 ± 10.5 millimetre of mercury (mmHg) |
|---|
| Riociguat >=6 to <18 Years | -2.4 ± 10.0 millimetre of mercury (mmHg) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.